SCHEMBL4397908

SCHEMBL4397908

Cc1cccc(-n2c(-c3sc(Nc4ccccc4)nc3C)nc3ccccc3c2=O)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JUN P05412 7/20 0.70
NFKB1 P19838 5/20 0.70
NFKB2 Q00653 5/20 0.70
RELA Q04206 5/20 0.70
MEN1 O00255 4/20 0.58
KMT2A Q03164 4/20 0.58
LMNA P02545 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
PLA2G1B P04054 1/20 0.58
HPGD P15428 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
ATG4B Q9Y4P1 1/20 0.58
POLB P06746 3/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
PSMD14 O00487 1/20 0.53
MMP2 P08253 1/20 0.53
PTPN7 P35236 1/20 0.53
PPARG P37231 1/20 0.53
DUSP3 P51452 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4401622 0.93 JUN (0.82) JUNNFKB1NFKB2RELAMEN1
SCHEMBL4392950 0.92 JUN (0.82) JUNNFKB1NFKB2RELAMEN1
SCHEMBL4391571 0.90 JUN (0.72) JUNNFKB1NFKB2RELAMEN1
SCHEMBL4402480 0.89 JUN (0.67) JUNNFKB1NFKB2RELAMEN1
SCHEMBL4395500 0.89 JUN (0.70) JUNNFKB1NFKB2RELAMEN1
SCHEMBL4393384 0.89 JUN (0.81) JUNNFKB1NFKB2RELAMEN1
SCHEMBL4397939 0.84 JUN (0.96) JUNNFKB1NFKB2RELAMEN1
SCHEMBL4392963 0.84 JUN (0.96) JUNNFKB1NFKB2RELAMEN1
SCHEMBL4402503 0.84 JUN (0.65) JUNNFKB1NFKB2RELAMEN1
SCHEMBL4398122 0.83 JUN (0.81) JUNNFKB1NFKB2RELAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007393-B1 THIAZOLE AND THIOPHENE ANALOGUES, AND THEIR USE IN TREATING AUTOIMMUNE DISEASES AND CANCERS UNIV LOUISIANA STATE (US) 2013-08-21 EP disclosed
US-8217037-B2 Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2012-07-10 US disclosed
US-20090306073-A1 Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers B.V. PATEL PHARMACEUTICAL EDUCATION & RESEARCH DEVELOPMENT (PERD) CENTRE (IN) 2009-12-10 US disclosed
EP-2007393-A2 THIAZOLE AND THIOPHENE ANALOGUES, AND THEIR USE IN TREATING AUTOIMMUNE DISEASES AND CANCERS Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College (US) 2008-12-31 EP disclosed
WO-2007118149-A2 THIAZOLE AND THIOPHENE ANALOGUES, AND THEIR USE IN TREATING AUTOIMMUNE DISEASES AND CANCERS BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL LOLLEGE (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306073-A1 Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers TPMT, TST, SSB JUN 2228/4885NFKB1 1188/4885NFKB2 1441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.